The effectiveness of helmets in reducing head injuries and hospital treatment costs: a multicentre study

2013 ◽  
Vol 198 (8) ◽  
pp. 415-417 ◽  
Author(s):  
Michael M Dinh ◽  
Kate Curtis ◽  
Rebecca Ivers
Keyword(s):  
Multicentre Study ◽  
Head Injuries ◽  
Treatment Costs ◽  
Hospital Treatment

scholarly journals Hospital Treatment Costs and Factors Affecting These Costs in Community-Acquired Pneumonia

2015 ◽  
Vol 16 (3) ◽  
pp. 107-113 ◽  
Author(s):  
Fatma Tokgoz Akyil ◽  
Armagan Hazar ◽  
Ipek Erdem ◽  
Canan Pehlivan Ones ◽  
Murat Yalcinsoy ◽  
...  
Keyword(s):  
Community Acquired Pneumonia ◽  
Treatment Costs ◽  
Hospital Treatment ◽  
Factors Affecting

scholarly journals Hospital-treated injuries from horse riding in Victoria, Australia: time to refocus on injury prevention?

2018 ◽  
Vol 4 (1) ◽  
pp. e000321 ◽  
Author(s):  
Siobhán O’Connor ◽  
Peta L Hitchens ◽  
Lauren V Fortington
Keyword(s):  
Injury Prevention ◽  
New Technology ◽  
Head Injuries ◽  
Incidence Rates ◽  
Hospital Treatment ◽  
Injury Incidence ◽  
Public And Private ◽  
Horse Riding ◽  
Public And Private Hospitals ◽  
Mean Cost

BackgroundThe most recent report on hospital-treated horse-riding injuries in Victoria was published 20 years ago. Since then, injury countermeasures and new technology have aimed to make horse riding safer for participants. This study provides an update of horse-riding injuries that required hospital treatment in Victoria and examines changes in injury patterns compared with the earlier study.MethodsHorse-riding injuries that required hospital treatment (hospital admission (HA) or emergency department (ED) presentations) were extracted from routinely collected data from public and private hospitals in Victoria from 2002–2003 to 2015–2016. Injury incidence rates per 100 000 Victorian population per financial year and age-stratified and sex-stratified injury incidence rates are presented. Poisson regression was used to examine trends in injury rates over the study period.ResultsED presentation and HA rates were 31.1 and 6.6 per 100 000 person-years, increasing by 28.8% and 47.6% from 2002 to 2016, respectively. Female riders (47.3 ED and 10.1 HA per 100 000 person-years) and those aged between 10 and 14 years (87.8 ED and 15.7 HA per 100 000 person-years) had the highest incidence rates. Fractures (ED 29.4%; HA 56.5%) and head injuries (ED 15.4%; HA 18.9%) were the most common injuries. HA had a mean stay of 2.6±4.1 days, and the mean cost per HA was $A5096±8345.ConclusionHorse-riding injuries have remained similar in their pattern (eg, types of injuries) since last reported in Victoria. HA and ED incidence rates have increased over the last 14 years. Refocusing on injury prevention countermeasures is recommended along with a clear plan for implementation and evaluation of their effectiveness in reducing injury.

scholarly journals Hospital treatment costs and length of stay associated with hypertension and multimorbidity after hemorrhagic stroke

BMC Neurology ◽  
2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Adrian V. Specogna ◽  
Tanvir C. Turin ◽  
Scott B. Patten ◽  
Michael D. Hill
Keyword(s):  
Length Of Stay ◽  
Hemorrhagic Stroke ◽  
Treatment Costs ◽  
Hospital Treatment

scholarly journals TREATMENT COSTS FOR COVID-19 PATIENTS IN A TERTIARY HOSPITAL FROM SERBIA

2021 ◽  
Author(s):  
Predrag S. Sazdanovic ◽  
Slobodan Milisavljevic ◽  
Dragan R. Milovanovic ◽  
Slobodan M. Jankovic ◽  
Dejan Baskic ◽  
...  
Keyword(s):  
Fatal Outcome ◽  
Tertiary Hospital ◽  
Treatment Costs ◽  
Hospital Treatment ◽  
Insurance Fund ◽  
Southeast Europe ◽  
Middle Income ◽  
Tertiary Center ◽  
Illness Study ◽  
Comorbidity Index

ABSTRACTIntroductionAim of our study was to identify total costs of COVID-19 inpatients treatment in an upper-middle income country from Southeast Europe.MethodsThis retrospective, observational cost of illness study was performed from National Health Insurance Fund perspective and included a cohort of 118 males and 78 females admitted to COVID-19 ward units of a tertiary center, during the first wave of epidemics.ResultsThe median of total costs in the non-survivors’ subgroup (n=43) was 3279.16 Euro (4023.34, 355.20, 9909.61) which is higher than in the survivors (n=153) subgroup 747.10 Euro (1088.21, 46.71, 3265.91). The odds ratio of Charlson Comorbidity Index total score and every 100-Euros increase of patient’s total hospital treatment costs for fatal outcome were 1.804 (95% confidence interval 1.408-2.311, p<0.001) and 1.050 (1.029-1.072, p<0.001), respectively.ConclusionsDirect medical treatment costs for COVID-19 inpatients represent significant economic burden. The link between increased costs and unfavorable final outcome should be further explored.

scholarly journals Economic aspects of hospital treated pneumococcal pneumonia and the results of Pneumo 23 vaccine use in Serbia

2008 ◽  
Vol 136 (11-12) ◽  
pp. 625-628
Author(s):  
Tatjana Adzic ◽  
Ilija Rosic ◽  
Dragana Jovanovic ◽  
Snezana Medic-Stojanac
Keyword(s):  
Streptococcus Pneumoniae ◽  
Treatment Cost ◽  
Lung Diseases ◽  
Pneumococcal Pneumonia ◽  
Pneumococcal Infection ◽  
Treatment Costs ◽  
Hospital Treatment ◽  
Chronic Obstructive ◽  
Clinical Centre ◽  
One Year

INTRODUCTION In Serbia, there is a significant number of persons suffering of pneumococcal pneumonia. Persons aged 65 years or older, immunocompromised patients, patients with co-morbidities, such as chronic obstructive lung disease and congestive heart failure, are at the highest risk for developing pneumococcal pneumonia. Most of the patients are treated empirically, although it is often overlooked that Streptococcus pneumoniae can be resistant to the used antibiotics. The treatment costs of such inpatients and outpatients are very high. In Serbia, immunization of persons at risk to develop the diseases caused by Streptococcus pneumoniae is carried out using pneumococcus polysaccharide vaccine according to clinical indications. The exact number of immunized persons and the total number of registered patients are still unknown, but it is certain of being unjustifiably low. OBJECTIVE The goal of the study was to investigate, during a one-year period, the number and basic characteristics of persons hospitably treated for pneumonia, the type of cause of the infection, applied antibiotic medications, duration and costs of hospital treatment at the Institute for Lung Diseases and Tuberculosis of the Clinical Centre of Serbia in Belgrade. METHOD We retrospectively analyzed the medical records of patients with pneumonia treated at the Institute for Lung Diseases and Tuberculosis of the Clinical Centre of Serbia in Belgrade during 2006. RESULTS During the observed one-year period, 290 patients underwent hospital treatment, of whom the cause of the infection was confirmed in 116 (40%). The average duration of hospitalization was 12 days, with treatment cost of 32,031.74 RSD (402.42 EUR) per patient. The treatment cost per patient including general and intensive care was 18,290.01 RSD (229.78 EUR). The distribution cost of Pneumo 23 vaccine in Serbia, without purchase tax, was 746.90 RSD (9.38 EUR). CONCLUSION Pneumococcal pneumonia is a significant medical and economic problem for the healthcare system of Serbia. The use of antipneumococcal vaccination can be useful in decreasing the overall treatment costs related to pneumococcal infection.

Hospital treatment costs of exacerbations in COPD patients with indications for LTOT

2015 ◽  
Author(s):  
Nikolay Kyuchukov ◽  
Plamen Pavlov ◽  
Pavlina Glogovska ◽  
Tsania Popova ◽  
Nikolay Yanev ◽  
...  
Keyword(s):  
Treatment Costs ◽  
Hospital Treatment ◽  
Copd Patients

scholarly journals Smoking Attributable Hospital Treatment, Treatment Costs and Smoking Attributable Mortality in the Czech Republic in 2002

2007 ◽  
Vol 15 (2) ◽  
pp. 79-83 ◽  
Author(s):  
Hana Sovinová ◽  
Ladislav Csémy ◽  
Bohumír Procházka ◽  
Stanislava Kottnauerová
Keyword(s):  
Czech Republic ◽  
Treatment Costs ◽  
Attributable Mortality ◽  
Hospital Treatment ◽  
The Czech Republic
Sign in / Sign up

Export Citation Format

Share Document